Literature DB >> 2121626

Chemical enhancement of cisplatin cytotoxicity in a human ovarian and cervical cancer cell line.

G M Boike1, E Petru, B U Sevin, H E Averette, T C Chou, M Penalver, D Donato, M Schiano, S G Hilsenbeck, J Perras.   

Abstract

While many advances have been made in the chemotherapy of gynecologic cancers, treatment failures remain a major clinical problem. A growing understanding of the mechanisms of tumor cell resistance to antineoplastic drugs provides a framework for the development of chemotherapy regimens containing agents capable of modulating tumor response. Using a short-term ATP bioluminescence assay we studied the ability of two methylxanthines (caffeine, pentoxifylline) and an inhibitor of ADP-ribosyl transferase (3-aminobenzamide) to enhance cisplatin cytotoxicity in gynecologic cancer cell lines. Our findings of significantly enhanced cisplatin-induced cytotoxicity with two different analysis techniques confirms the effectiveness of these agents. These results may have future clinical significance.

Entities:  

Mesh:

Substances:

Year:  1990        PMID: 2121626     DOI: 10.1016/0090-8258(90)90065-s

Source DB:  PubMed          Journal:  Gynecol Oncol        ISSN: 0090-8258            Impact factor:   5.482


  3 in total

1.  Combination effects of poly(ADP-ribose) polymerase inhibitors and DNA-damaging agents in ovarian tumor cell lines--with special reference to cisplatin.

Authors:  F Bernges; W J Zeller
Journal:  J Cancer Res Clin Oncol       Date:  1996       Impact factor: 4.553

2.  Cranial radiation and concomitant cisplatin and mitomycin-C plus resistance modulators for malignant gliomas.

Authors:  D J Stewart; S Dahrouge; O Agboola; A Girard
Journal:  J Neurooncol       Date:  1997-04       Impact factor: 4.130

3.  Caffeine markedly sensitizes human mesothelioma cell lines to pemetrexed.

Authors:  Sang Hee Min; I David Goldman; Rongbao Zhao
Journal:  Cancer Chemother Pharmacol       Date:  2007-06-27       Impact factor: 3.333

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.